
    
      Approximately 45 participants will be assigned first to pembrolizumab + oxaliplatin + TS-1
      combination therapy (Cohort 1), and then 45 participants will be assigned to pembrolizumab +
      cisplatin + TS-1 combination therapy (Cohort 2).
    
  